DANIEL M JUNIUS

CIK 1094159 · Chief Executive Officer · last filed 2026-05-14

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.00M

Companies

4

Total Filings

125

Lifetime Open-Market Net

-$12.12M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IDXX Director 3,561 $560.88 $2.00M -$8.93M 60 2026-05-14
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director 98,459 $15.70 $1.55M $214.1K 17 2024-05-01
ImmunoGen, Inc. (IMGN) Delisted Director 209,987 $31.23 $6.56M -$3.40M 46 2018-03-16
Vitae Pharmaceuticals, Inc (VTAE) Delisted Director $0 2 2016-10-25

Recent Filings · Page 4 of 13

125 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2021-05-04 IDXX Grant (A) +11 $6.0K EDGAR
2021-02-24 IDXX Mixed -$865.8K EDGAR
2021-02-03 IDXX Grant (A) +13 $6.2K EDGAR
2020-11-02 IDXX Grant (A) +15 $6.4K EDGAR
2020-08-21 IDXX Mixed -$1.19M EDGAR
2020-08-03 IDXX Grant (A) +13 $4.8K EDGAR
2020-05-27 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
2020-05-20 IDXX Mixed +8,000 $1.44M EDGAR
2020-05-08 IDXX Grant (A) $0 EDGAR
2020-03-10 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +20,000 $68.0K EDGAR
Showing 3140 of 125
Page 4 of 13
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.